| Texto completo | |
| Autor(es): Mostrar menos - |
Pires Farias, Jessica
;
Souza, Milena Silva
;
Costa Fogaca, Mayanna Moreira
;
da Silva Brito, Ruth Dalety
;
da Rocha Santos, Amanda
;
de Melo, Cristiane Moutinho Lagos
;
de Sousa, Georon Ferreira
;
Braconi, Carla Torres
;
Lopes Barboza, Mario Gabriel
;
de Souza Lino, Vanesca
;
Donizetti Candido, Erika
;
Oliveira Vidal, Paloma
;
Rebello Pinho, Joao Renato
;
Leal Oliveira, Danielle Bruna
;
Durigon, Edison Luiz
;
de Souza Ferreira, Luis Carlos
;
Amorim, Jaime Henrique
Número total de Autores: 17
|
| Tipo de documento: | Artigo Científico |
| Fonte: | EXPERT REVIEW OF VACCINES; v. 24, n. 1, p. 9-pg., 2025-12-31. |
| Resumo | |
BackgroundThe COVID-19 vaccination campaign for children in Brazil evolved gradually from 2021 to the present, adapting to regulatory framework from the Brazilian Health Regulatory Agency (ANVISA). However, while adults received updated vaccines targeting newer variants, children and adolescents continued to receive vaccines based on the original wild-type strain.Research design and methodsThis study evaluates the vaccine-induced protective immunity, measured by serum antibody and neutralization responses, in vaccinated (n = 61) and unvaccinated (n = 13) pediatric populations against the wild-type (WT), Omicron BA.1, and JN.1 SARS-CoV-2 variants.ResultsVaccinated children exhibited significantly higher antibody levels and neutralization titers against WT compared to unvaccinated peers (p <= 0.0001). However, responses to BA.1 were drastically reduced, and JN.1 subvariant neutralization was limited in both groups. Immunoinformatic analysis revealed a marked decline in conserved neutralizing antibody-targeting epitopes within the Spike protein: from 465 in WT to 49 in BA.1 and 41 in JN.1. This substantial antigenic drift underscores the immunological gap created by vaccinating children with outdated formulations.ConclusionsOur findings highlight the urgent need for updating pediatric vaccines to include antigens from circulating virus variants in order to increase immune protection and reduce susceptibility to infection and controlling community transmission. (AU) | |
| Processo FAPESP: | 22/11981-1 - Vacinação contra a COVID-19: entendendo o passado e o presente e projetando o futuro |
| Beneficiário: | Luis Carlos de Souza Ferreira |
| Modalidade de apoio: | Auxílio à Pesquisa - Pesquisador Visitante - Brasil |
| Processo FAPESP: | 23/01925-0 - Vacinação contra a COVID- 19: de onde viemos, onde estamos e para onde vamos? |
| Beneficiário: | Jessica Pires Farias |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 23/07746-0 - Drug discovery contra doenças infecciosas virais humanas |
| Beneficiário: | Carsten Wrenger |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |
| Processo FAPESP: | 20/06409-1 - Avaliação da resposta imune humoral e da resposta inflamatória em pacientes com diagnóstico confirmado de COVID-19 no Hospital Sírio Libanês e correlação com a severidade da doença |
| Beneficiário: | Edison Luiz Durigon |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 20/05204-7 - Desenvolvimento de nanovacinas proteicas que se auto-estruturam contra SARS-CoV-2 |
| Beneficiário: | Luis Carlos de Souza Ferreira |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |